First Time Loading...

Galecto Inc
NASDAQ:GLTO

Watchlist Manager
Galecto Inc Logo
Galecto Inc
NASDAQ:GLTO
Watchlist
Price: 0.78 USD 3.38% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

GLTO's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. [ Read More ]

The intrinsic value of one GLTO stock under the Base Case scenario is 1.22 USD. Compared to the current market price of 0.78 USD, Galecto Inc is Undervalued by 36%.

Key Points:
GLTO Intrinsic Value
Base Case
1.22 USD
Undervaluation 36%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Galecto Inc

Backtest GLTO Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling GLTO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Galecto Inc

Current Assets 36.8m
Cash & Short-Term Investments 33.2m
Receivables 2.8m
Other Current Assets 859k
Non-Current Assets 1.5m
PP&E 325k
Other Non-Current Assets 1.1m
Current Liabilities 5.8m
Accounts Payable 1.7m
Accrued Liabilities 2.9m
Other Current Liabilities 1.2m
Non-Current Liabilities 66k
Other Non-Current Liabilities 66k
Efficiency

Earnings Waterfall
Galecto Inc

Revenue
0 USD
Operating Expenses
-36.5m USD
Operating Income
-36.5m USD
Other Expenses
-1.9m USD
Net Income
-38.3m USD

Free Cash Flow Analysis
Galecto Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

GLTO Profitability Score
Profitability Due Diligence

Galecto Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Galecto Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

GLTO Solvency Score
Solvency Due Diligence

Galecto Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Galecto Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GLTO Price Targets Summary
Galecto Inc

There are no price targets for GLTO.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

GLTO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

GLTO Price
Galecto Inc

1M 1M
+11%
6M 6M
+7%
1Y 1Y
-59%
3Y 3Y
-88%
5Y 5Y
-95%
10Y 10Y
-95%
Annual Price Range
0.78
52w Low
0.521
52w High
3.17
Price Metrics
Average Annual Return -51.03%
Standard Deviation of Annual Returns 31.51%
Max Drawdown -97%
Shares Statistics
Market Capitalization 21.1m USD
Shares Outstanding 27 104 777
Percentage of Shares Shorted 0.27%

GLTO Return Decomposition
Main factors of price return

What is price return decomposition?

GLTO News

Other Videos

Company Profile

Galecto Inc Logo
Galecto Inc

Country

Denmark

Industry

Biotechnology

Market Cap

21.1m USD

Dividend Yield

0%

Description

Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. The firm is focused on developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. The Company’s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). The firm is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate portfolio also includes GB1211, a selective oral galectin-three inhibitor, which is being developed for the treatment of fibrosis related to non-alcoholic steatohepatitis (NASH), and GB2064, a selective oral inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which fibrosis reduces the ability to form blood cells.

Contact

COPENHAGEN
Galecto Biotech Ab, Ole Maaloes Vej3
+4570705210.0
https://galecto.com/

IPO

2020-10-29

Employees

40

Officers

Co-Founder, President, CEO & Director
Dr. Hans T. Schambye M.D., Ph.D.
Chief Financial Officer
Mr. Jonathan P. Freve CPA, CPA
Co-Founder
Dr. Hakon Leffler
Co-Founder & Member of the Clinical Advisory Board - IPF
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP
Senior VP, General Counsel & Corporate Secretary
Mr. Garrett Winslow Esq.

See Also

Discover More
What is the Intrinsic Value of one GLTO stock?

The intrinsic value of one GLTO stock under the Base Case scenario is 1.22 USD.

Is GLTO stock undervalued or overvalued?

Compared to the current market price of 0.78 USD, Galecto Inc is Undervalued by 36%.